Research programme: neurological disorders therapies - Lexicon Pharmaceuticals/Bristol-Myers Squibb

Drug Profile

Research programme: neurological disorders therapies - Lexicon Pharmaceuticals/Bristol-Myers Squibb

Alternative Names: LG 262; LG 317; LG 324; LG 351; LG 451; LG 470; LG 487; LG 527; LG 590; LG 726; LG 752; LG 852; LG 915; LX 9211

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Lexicon Genetics
  • Developer Bristol-Myers Squibb; Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Neuropathic pain

Most Recent Events

  • 07 Nov 2016 LX 9211 licensed to Lexicon Pharmaceuticals worldwide
  • 15 Apr 2015 Preclinical development is ongoing in USA
  • 21 Jan 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top